PRESS RELEASES

• Results from immunotherapy based clinical trials including HalioDx’s Immunoscore®_CR  and Immunosign®, will be...

• Immunoscore® is now fully reimbursed by a first Major Private Medical Insurer in the UK 

HalioDx, an immuno-oncology...

HalioDx, an immuno-oncology company pioneering the immunological diagnosis of cancers, today announced that the company...

• 9 agreements covering 19 countries signed in 2018
• Potential of 56 000 Immunoscore® tests annually for early-stage...

• Jérôme Galon and colleagues demonstrated that the tumor immune microenvironment status recapitulated by Immunoscore®...

• Brightplex allows to analyze up to 7 biomarkers on the same slide
• It utilizes brightfield and standardized reagents...

HalioDx SAS, an immuno-oncology diagnostic company, today announced that Pronto Diagnostics will market and distribute...

HalioDx SAS, an immuno-oncology diagnostic company, today announced that it has signed a distribution agreement with...

HalioDx SAS, an immuno-oncology diagnostic company, announced today that Everything Genetic Ltd. will market and...

• An international consortium confirms the strong prognostic value of the Immunoscore® assay in early stage colon...

HalioDx SAS, an immuno-oncology diagnostic company, today announced that Immunoscore® Colon CE-IVD workflow is now...

• COLOSSUS aim is to better stratify metastatic colorectal patients for improving treatments

• The project gathers a...

• This round was led by PSIM fund managed by Bpifrance in the framework of the program ‘Investing for the Future’
• This...

• HalioDx immune scoring solutions results presented by our biopharma partners at SITC 2017 
• Halioseek® PD-L1/CD8...

• Halioseek® is now CE-IVD and can be used for % PD-L1 Tumor Cells assessment in Non-Small Cell Lung Cancer (NSCLC)
• Per...

• Objective: Evaluate Immunoscore® as a key risk-factor to optimally adapt chemotherapy prescription in stage III CC...

• HalioDx focuses on exploring and validating the performance of its proprietary diagnostic solutions in multiple cancer...

• HalioDx received CMS CLIA Compliance for its laboratory based in Marseille
• Immunoscore® Colon, is now available to US...